Physician profile
Javed Syed
NPI 1891718417
$8,531.90
in general payments reported to CMS, 2019-2025
35 companies · $2,743 in 2025
The $2,743 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $243 · 2021: $615 · 2022: $1,573 · 2023: $1,247 · 2024: $1,709 · 2025: $2,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,498 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,497.83 |
| Education | $201.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $898.56 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $825.37 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $781.14 | 2021-2025 | Tavneos, Krystexxa, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $643.48 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $569.86 | 2020-2025 | Terlivaz, Acthar |
| Calliditas Therapeutics US INC. | $532.74 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $437.36 | 2023-2025 | |
| Akebia Therapeutics INC | $360.41 | 2021-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $357.71 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $335.15 | 2021-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $298.99 | 2020-2025 | Rayaldee |
| Vifor Pharma, INC. | $291.53 | 2021-2025 | Veltassa |
| Glaxosmithkline, LLC. | $289.05 | 2020-2024 | Benlysta, Jesduvroq |
| Ani Pharmaceuticals, INC. | $264.44 | 2022-2024 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $194.74 | 2021-2023 | Krystexxa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Renalytix Ai, INC. | $148.81 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $140.97 | 2019-2024 | Gattex |
| Ardelyx, INC. | $133.39 | 2024-2025 | Ibsrela |
| Apellis Pharmaceuticals, INC. | $128.76 | 2025 | Empaveli |
| Kyowa Kirin, INC. | $120.16 | 2024-2025 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.67 | 2024-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $99.92 | 2022-2024 | Givlaari, Onpattro |
| Vantive US Healthcare LLC | $89.10 | 2025 | Renal - Pd |
| Novo Nordisk INC | $63.83 | 2021-2023 | Ozempic |
| Janssen Pharmaceuticals, INC | $63.27 | 2019 | |
| Fresenius USA Marketing, INC. | $59.66 | 2021-2025 | Velphoro |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $55.82 | 2025 | Voyxact |
| Veloxis Pharmaceuticals, INC. | $53.93 | 2019 | |
| Scpharmaceuticals INC. | $46.96 | 2025 | |
| Genentech USA, INC. | $30.00 | 2019 | |
| Mallinckrodt Enterprises LLC | $25.99 | 2019 | |
| Nuwellis, INC. | $23.57 | 2022 | |
| Lilly USA, LLC | $16.58 | 2025 | Jardiance |
| Ethicon US, LLC | $16.07 | 2019 | |
| Baxter Healthcare | $15.91 | 2024 | Renal - Pd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javed Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.